Historically, it takes an average of 17 years for new treatments to move from clinical
evidence to daily practice. Given the highly effective treatments now available to prevent or …

Renal fibrosis (RF) is the end stage of several chronic kidney diseases. Its series of changes
include excessive accumulation of extracellular matrix, epithelial-mesenchymal transition …

The highest financial and symptom burdens and the lowest health-related quality-of-life
scores are seen in people with kidney failure. A total of 11 countries in the International …

Background: Chronic kidney disease (CKD) is an important but insufficiently recognized
public health problem. Unprecedented advances in delaying progression of CKD and …

Chronic kidney disease (CKD) affects about 850 million people worldwide and is projected
to be the fifth leading cause of death by 2040. Individuals from low-and middle-income …

Health care on a global scale significantly contributes to carbon emissions, with high-income
countries being the primary culprits. Within health care, dialysis plays a significant role as a …

Background The term “resource-limited setting” has often been used to broadly describe
“low resource settings,” or “low-and middle-income countries”(LMICs). Various inter-related …

Individuals, societies, and the environment are affected by neglected and emerging
diseases. These diseases result in a variety of severe outcomes, including permanent …

The high global burden of kidney disease highlights an urgent need for early diagnosis and
the implementation of interventions to prevent disease progression. Such an approach …

In low-and lower-middle-income countries (LLMICs), delivering equitable kidney care
presents substantial challenges, resulting in significant disparities in disease management …